{
    "clinical_study": {
        "@rank": "165019", 
        "brief_summary": {
            "textblock": "To determine the tolerance and side effects of a combination of lentinan and didanosine\n      (ddI) compared with ddI alone. To determine whether the combination of lentinan and ddI\n      produces a significant immunorestorative effect within the study observation period (6-12\n      months) as measured by an increase in one or more of the following: neutrophil count and\n      activity, T-cell subsets, and a decrease in p24 antigen."
        }, 
        "brief_title": "Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive either lentinan (40 patients) or placebo (10 patients) in\n      combination with ddI for at least 26 weeks; those tolerating their dose may be offered\n      continuation of therapy for an additional 26 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV seropositivity.\n\n          -  Absolute CD4 count of 200 - 500 cells/mm3.\n\n          -  No active opportunistic infection or Kaposi's sarcoma.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior ddI for no longer than 3 months.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Lymphoid malignancy.\n\n          -  Pancreatitis.\n\n          -  Peripheral neuropathy.\n\n          -  Critical illness.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antiretroviral agents other than ddI.\n\n          -  Steroids.\n\n          -  Cytotoxic agents.\n\n          -  Immunosuppressive agents.\n\n          -  Immunomodulators.\n\n          -  1-Thyroxine.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiotherapy.\n\n        Prior Medication:\n\n        Excluded within 1 month prior to study entry:\n\n          -  Antiretroviral agents other than ddI (patients may have received prior ddI for no\n             longer than 3 months total).\n\n          -  Steroids.\n\n          -  Cytotoxic agents.\n\n          -  Immunosuppressive agents.\n\n          -  Immunomodulators.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiotherapy within 1 month prior to study entry. Active drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "50", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002098", 
            "org_study_id": "126A", 
            "secondary_id": "91-10-15"
        }, 
        "intervention": [
            {
                "intervention_name": "Lentinan", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Lentinan"
            ]
        }, 
        "keyword": [
            "Didanosine", 
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Lentinan"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94109"
                    }, 
                    "name": "ViRx Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maitland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32751"
                    }, 
                    "name": "Goodgame Med Group"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients", 
        "overall_official": [
            {
                "last_name": "Lang W", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Goodgame J", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "8721897", 
                "citation": "Gordon M, Guralnik M, Kaneko Y, Mimura T, Goodgame J, DeMarzo C, Pierce D, Baker M, Lang W. A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3. J Med. 1995;26(5-6):193-207."
            }, 
            {
                "citation": "Kaneko Y, Mimura T, Guralnik M, Baker M, Goodgame J, DeMarzo C, Pierce D, Lang W, Gordon M. Phase II study of combination of lentinan with ddI in HIV-positive patients. Int Conf AIDS. 1994 Aug 7-12;10(1):212 (abstract no PB0276)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002098"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AJI Pharma USA", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1995"
    }, 
    "geocoordinates": {
        "Goodgame Med Group": "28.628 -81.363", 
        "ViRx Inc": "37.775 -122.419"
    }
}